
LRMR
Healthcare · Biotechnology · $313.7M market cap
$3.02+0.32 (+11.9%)Nov 13, 4:21 PM EST
Next report
Time not confirmed
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · -2.2% over 90 days · 30-day revisions 6 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 18, 2026 · upcoming | Time not confirmed | -0.35 | -0.61 | -74.3% |
| Aug 4, 2026 | Before the open | -0.39 | -0.30 | +23.1% |
| May 14, 2026 | Before the open | -0.59 | -0.31 | +47.5% |
| Mar 18, 2026 | Time not confirmed | -0.49 | -0.73 | -49.0% |
| Nov 5, 2025 | Before the open | -0.39 | -0.61 | -56.4% |
| Aug 14, 2025 | Before the open | -0.49 | -0.41 | +16.3% |
| Apr 30, 2025 | Before the open | -0.41 | -0.46 | -12.2% |
| Mar 12, 2025 | Before the open | -0.32 | -0.45 | -40.9% |
| Oct 30, 2024 | Before the open | -0.37 | -0.24 | +35.1% |
| Aug 7, 2024 | Before the open | -0.32 | -0.34 | -6.3% |
| May 9, 2024 | After the close | -0.24 | -0.27 | -12.5% |
| Mar 14, 2024 | After the close | -0.25 | -0.30 | -20.0% |
| Nov 14, 2023 | After the close | -0.23 |
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
| -0.21 |
| +8.7% |
| Aug 10, 2023 | Before the open | -0.21 | -0.19 | +9.5% |
| May 15, 2023 | Before the open | -0.25 | -0.15 | +40.0% |
| Mar 14, 2023 | Before the open | -0.37 | -0.21 | +43.2% |
| Nov 10, 2022 | Before the open | -0.42 | -0.37 | +11.9% |
| Aug 11, 2022 | After the close | -0.57 | -0.47 | +17.5% |
| May 12, 2022 | Before the open | -0.51 | -0.49 | +3.9% |
| Mar 25, 2022 | Before the open | -0.72 | -0.50 | +30.6% |
| Nov 12, 2021 | Before the open | -0.66 | -0.92 | -39.4% |
| Aug 12, 2021 | Before the open | -0.75 | -0.79 | -5.3% |
| May 10, 2021 | After the close | -0.86 | -0.76 | +11.6% |
| Mar 4, 2021 | Before the open | -0.70 | -0.89 | -27.1% |
| Nov 10, 2020 | Before the open | -2.28 | -0.64 | +71.9% |
| Aug 11, 2020 | Before the open | -2.16 | -1.21 | +44.0% |
| May 8, 2020 | After the close | -2.28 | -1.20 | +47.4% |
| Mar 5, 2020 | After the close | -2.28 | -2.28 | 0.0% |
| Nov 6, 2019 | After the close | -3.20 | -2.88 | +10.0% |
| Aug 8, 2019 | After the close | -4.38 | -3.84 | +12.3% |
| May 9, 2019 | After the close | -5.09 | -4.20 | +17.5% |
| Mar 11, 2019 | After the close | -5.26 | -4.68 | +11.0% |
| Nov 7, 2018 | After the close | -5.64 | -4.92 | +12.8% |
| Aug 7, 2018 | After the close | -7.08 | -6.84 | +3.4% |
| May 8, 2018 | After the close | -6.18 | -6.96 | -12.6% |
| Mar 6, 2018 | After the close | -6.84 | -5.76 | +15.8% |